Aberrant expression of β-catenin in CD4+ T cells isolated from primary progressive multiple sclerosis patients
暂无分享,去创建一个
[1] Bernhard Hemmer,et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.
[2] S. Manicassamy,et al. Modulation of Inflammatory Responses by Wnt/β-Catenin Signaling in Dendritic Cells: A Novel Immunotherapy Target for Autoimmunity and Cancer , 2016, Front. Immunol..
[3] P. Sørensen,et al. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects , 2016, Therapeutic advances in neurological disorders.
[4] E. Mazzon,et al. Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action? , 2015, Current molecular medicine.
[5] G Giovannoni,et al. The evidence for a role of B cells in multiple sclerosis , 2012, Neurology.
[6] K. Hawker,et al. Progressive multiple sclerosis: characteristics and management. , 2011, Neurologic clinics.
[7] E. Arenas,et al. Emerging roles of Wnts in the adult nervous system , 2010, Nature Reviews Neuroscience.
[8] S. Galande,et al. Global Regulator SATB1 Recruits β-Catenin and Regulates TH2 Differentiation in Wnt-Dependent Manner , 2010, PLoS biology.
[9] M. Mandal,et al. β-Catenin/Tcf Determines the Outcome of Thymic Selection in Response to αβTCR Signaling1 , 2009, The Journal of Immunology.
[10] D. Rowitch,et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. , 2009, Genes & development.
[11] J. Lafaille,et al. Swift Entry of Myelin-Specific T Lymphocytes into the Central Nervous System in Spontaneous Autoimmune Encephalomyelitis1 , 2008, The Journal of Immunology.